Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

Journal of Neuro-Oncology

Volumn 105, Issue 3, 2011, Pages 613-620

  Lin, Nancy U ^a   Eierman, Wolfgang ^b   Greil, Richard ^c   Campone, Mario ^d   Kaufman, Bella ^e   Steplewski, Klaudia ^f   Lane, Stephen R ^f   Zembryki, Denise ^f   Rubin, Stephen D ^f   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Frauenklinik Vom Roten Kreuz   (Germany)

^c Private Medical University Hospital   (Austria)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e SHEBA MEDICAL CENTER   (Israel)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Brain metastases; Breast cancer; Capecitabine; Lapatinib; Topotecan

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; STEREOTACTIC RADIOSURGERY; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT PLANNING; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, ERBB-2; TOPOTECAN;

EID: 82955163167     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0629-y     Document Type: Article

References (24)

1. JC Bendell SM Domchek HJ Burstein L Harris J Younger I Kuter C Bunnell M Rue R Gelman E Winer 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2972 2977 12784331 10.1002/cncr.11436 (Pubitemid 36676250)
2. HJ Stemmler S Kahlert W Siekiera M Untch B Heinrich V Heinemann 2006 Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer Breast (Edinb, Scotl) 15 219 225 1:STN:280:DC%2BD28zptVCqtA%3D%3D
3. NU Lin EP Winer 2007 Brain metastases: the HER2 paradigm Clin Cancer Res 13 1648 1655 17363517 10.1158/1078-0432.CCR-06-2478 1:CAS:528: DC%2BD2sXivV2gtro%3D (Pubitemid 46952930)
4. S Gori S Rimondini V De Angelis M Colozza G Bisagni G Moretti A Sidoni C Basurto C Aristei P Anastasi L Crino 2007 Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors Oncologist 12 766 773 17673608 10.1634/theoncologist.12-7-766 (Pubitemid 47328220)
5. H Kennecke R Yerushalmi R Woods MC Cheang D Voduc CH Speers TO Nielsen K Gelmon 2010 Metastatic behavior of breast cancer subtypes J Clin Oncol 28 3271 3277 20498394 10.1200/JCO.2009.25.9820
6. ME Melisko DH Moore PK Sneed J De Franco HS Rugo 2008 Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival J Neurooncol 88 359 365 18398574 10.1007/s11060-008- 9578-5
7. AF Eichler I Kuter P Ryan L Schapira J Younger JW Henson 2008 Survival in patients with brain metastases from breast cancer: the importance of HER-2 status Cancer 112 2359 2367 18361426 10.1002/cncr.23468 1:CAS:528: DC%2BD1cXnsFGjtbg%3D
8. B Gril D Palmieri JL Bronder JM Herring E Vega-Valle L Feigenbaum DJ Liewehr SM Steinberg MJ Merino SD Rubin PS Steeg 2008 Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain J Natl Cancer Inst 100 1092 1103 18664652 10.1093/jnci/djn216 1:CAS:528:DC%2BD1cXpslWktrc%3D
9. Kuhn J, Robins HI, Mehta M, Fine H, Cloughesy T, Wen P, Chang SM, DeAngelis L, Lieberman F, Reardon D, Abrey LE, Lassman AB, Adalpe K, Yung WKA, Grabinski J, Lamborn K, Prados M (2008) Tumor sequestration of lapatinib (NABTC 04-01). Neurooncology 10:abstr ET-05
10. NU Lin LA Carey MC Liu J Younger SE Come M Ewend GJ Harris E Bullitt AD Van den Abbeele JW Henson X Li R Gelman HJ Burstein E Kasparian DG Kirsch A Crawford F Hochberg EP Winer 2008 Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 26 1993 1999 18421051 10.1200/JCO.2007.12.3588 1:CAS:528:DC%2BD1cXlvFaqs7o%3D
11. NU Lin V Dieras D Paul D Lossignol C Christodoulou HJ Stemmler H Roche MC Liu R Greil E Ciruelos S Loibl S Gori A Wardley D Yardley A Brufsky JL Blum SD Rubin B Dharan K Steplewski D Zembryki C Oliva D Roychowdhury P Paoletti EP Winer 2009 Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 1452 1459 19228746 10.1158/1078-0432.CCR-08-1080 1:CAS:528:DC%2BD1MXitVOktLo%3D
12. CE Geyer J Forster D Lindquist S Chan CG Romieu T Pienkowski A Jagiello-Gruszfeld J Crown A Chan B Kaufman D Skarlos M Campone N Davidson M Berger C Oliva SD Rubin S Stein D Cameron 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
13. Geyer CE, Martin A, Newstat B, Casey MA, Berger MS, Oliva CR, Rubin SD, Stein S, Cameron D (2007) Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): updated efficacy and biomarker analysis. J Clin Oncol 25:40s (abstr 1035)
14. C Sung SM Blaney DE Cole FM Balis RL Dedrick 1994 A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid Cancer Res 54 5118 5122 7923128 1:CAS:528:DyaK2cXmt1Wjs74%3D (Pubitemid 24313487)
15. SD Baker RL Heideman WR Crom JF Kuttesch A Gajjar CF Stewart 1996 Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors Cancer Chemother Pharmacol 37 195 202 8529278 10.1007/BF00688317 1:CAS:528:DyaK28XmtlOmtg%3D%3D
16. C Oberhoff DG Kieback R Wurstlein H Deertz J Sehouli C van Soest J Hilfrich M Mesrogli G von Minckwitz HJ Staab AE Schindler 2001 Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study Onkologie 24 256 260 11455218 10.1159/000055088 1:STN:280: DC%2BD3Mvgtl2ntQ%3D%3D (Pubitemid 32664555)
17. C Erlichman SA Boerner CG Hallgren R Spieker XY Wang CD James GL Scheffer M Maliepaard DD Ross KC Bible SH Kaufmann 2001 The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux Cancer Res 61 739 748 11212277 1:CAS:528:DC%2BD3MXht1Gmt74%3D (Pubitemid 32128641)
18. Erlichman C, Adjei AA, Joy ME, Rubin SD, Friedman RA, Ames MM, Reid JM, Mandrekar S, Felten S, Molina JR (2005) A phase I study of lapatinib (GW572016) and topotecan in patients with solid tumors. Clin Cancer Res 11:8994s (abstr A8122)
19. JR Molina SH Kaufmann JM Reid SD Rubin M Galvez-Peralta R Friedman KS Flatten KM Koch TM Gilmer RJ Mullin RC Jewell SJ Felten S Mandrekar AA Adjei C Erlichman 2008 Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data Clin Cancer Res 14 7900 7908 19047120 10.1158/1078-0432.CCR-08-0415 1:CAS:528:DC%2BD1cXhsVegt77E
20. Boccardo F, Kaufman B, Baselga J, Dieras V, Link J, Casey MA, Fittipaldo A, Oliva C, Zembryki D, Rubin SD (2008) Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastses (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol 26:abstract 1094
21. Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, Bhatti R, Shehata M, Nouras H, Camburn T, Johnston SR (2010) Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 102:995-1002
22. G Metro J Foglietta M Russillo L Stocchi A Vidiri D Giannarelli L Crino P Papaldo M Mottolese F Cognetti A Fabi S Gori 2010 Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine Ann Oncol 22 625 630 20724575 10.1093/annonc/mdq434
23. M Ekenel AM Hormigo S Peak LM Deangelis LE Abrey 2007 Capecitabine therapy of central nervous system metastases from breast cancer J Neurooncol 85 223 227 17611719 10.1007/s11060-007-9409-0 1:CAS:528:DC%2BD2sXhtl2gs7rI (Pubitemid 47629405)
24. E Rivera C Meyers M Groves V Valero D Francis B Arun K Broglio G Yin GN Hortobagyi T Buchholz 2006 Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma Cancer 107 1348 1354 16909414 10.1002/cncr.22127 1:CAS:528: DC%2BD28XhtVOns73K (Pubitemid 44452785)